Sage Journals: Discover world-class research

Abstract

The common ultimate pathological feature for all cardiovascular diseases, congestive heart failure (CHF), is now considered as one of the main public health burdens that is associated with grave implications. Neurohormonal systems play a critical role in cardiovascular homeostasis, pathophysiology, and cardiovascular diseases. Hormone treatments such as the newly invented dual-acting drug valsartan/sacubitril are promising candidates for CHF, in addition to the conventional medications encompassing beta receptor blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists. Clinical trials also indicate that in CHF patients with low insulin-like growth factor-1 or low thyroid hormone levels, supplemental treatment with growth hormone or thyroid hormone seems to be cardioprotective; and in CHF patients with volume overload the vasopressin antagonists can relieve the symptoms superior to loop diuretics. Furthermore, a combination of selective glucocorticoid receptor agonist and mineralocorticoid receptor antagonist may be used in patients with diuretic resistance. Finally, the potential cardiovascular efficacy and safety of incretin-based therapies, testosterone or estrogen supplementation needs to be prudently evaluated in large-scale clinical studies. In this review, we briefly discuss the therapeutic effects of several key hormones in CHF.

Keywords

Congestive heart failure treatment hormone

Introduction

The common ultimate pathological feature for all cardiovascular diseases, congestive heart failure (CHF), is now considered as one of the main public health burdens that is associated with grave implications.¹ It is estimated that approximately 5.3 million people suffer from CHF (2.5% of adult Americans) and that approximately $60 billion per year is spent on the management of CHF in the US.^2,3 Despite advancements in pharmaceutical treatments and medical devices for CHF, the long-term mortality and morbidity of CHF is still unacceptably high, and the median 5-year survival is below 50%.⁴

Neurohormonal systems play a critical role in cardiovascular homeostasis, pathophysiology, and cardiovascular diseases. A large number of studies have established the crucial role played by the activated sympathetic nervous system in the decompensatory progression of CHF. Meanwhile, sympathetic suppressants, from peripheral beta receptor blockers to central sympatholytics that block sympathetic activation, can mitigate or protect the failing heart.⁵ In terms of the parasympathetic nervous system, vagus nerve afferent activation from the periphery can modulate efferent adrenergic and cholinergic neurons centrally and cholinergic neurons exert tonic inhibition of adrenergic neuron activation and of norepinephrine release from nerve terminals.⁵ Clinically, vagus nerve stimulation therapy, combined with chronic beta receptor blocker therapy, has been shown to further improve left ventricle (LV) function and reverse remodeling beyond what is achieved with beta receptor blockers alone.^5,6 Furthermore, endothelin-1 (ET-1) is the most abundant isoform of endothelin in the human cardiovascular system and this peptide induces vasoconstriction mainly via the endothelin A receptor.⁷ Experimental studies identified ET-1 as a regulator of the interaction between sympathetic neurons and cardiac myocytes that may be of clinical importance.⁷ However, nonselective and selective endothelin A receptor antagonists have not yet been approved for use due to lack of effectiveness in clinical trials for CHF.⁷

The renin–angiotensin–aldosterone system (RAAS) was the first neurohormonal system studied in CHF.⁸ Overactivation of the RAAS leads to increased cardiac injury and vascular endothelial damage, which predisposes to CHF.⁸ In addition to the direct hemodynamic effects, an imbalanced RAAS may cause heart dysfunction through mechanisms including inflammation, oxidative stress, and cardiac remodeling.⁸ The crucial finding that blockade of the RAAS significantly improves survival of CHF has formed the basis of current professional guidelines, which uniformly recommend inhibition of RAAS with an angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blockers (ARBs), and/or mineralocorticoid receptor antagonists (MRAs) as the standard treatment for CHF.⁸

To date, other hormones such as natriuretic peptides, incretins, growth hormone, vasopressin, glucocorticoids, thyroid hormone, and sex hormones have been intensively studied in an experimental animal model of CHF and in clinical trials. In this review, we briefly discuss the current understanding regarding the therapeutic effects of these key hormones in CHF.

Natriuretic peptides and neprilysin

Natriuretic peptides

Natriuretic peptides (NPs), encompassing atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), have demonstrated beneficial effects in CHF such as vasodilatation via suppressing the sympathetic activity and the RAAS.⁹ NPs also promote natriuresis via inhibiting the reabsorption of sodium and water in the distal and proximal nephron.⁹ Among the NPs, ANP is synthesized and secreted in the atria in response to distension, BNP is primarily synthesized and secreted by ventricular myocytes in response to volume overload-induced ventricular stretch, and CNP is synthesized by endothelial cells under the stimulation of acetylcholine, cytokine receptor agonists, or shear stress.⁹

Nesiritide is a recombinant human BNP that has undergone clinical trials in patients with acute decompensated heart failure (ADHF). Nesiritide acutely reduced heart failure symptoms and pulmonary capillary wedge pressure in these patients.^10,11 However, although nesiritide slightly reduced dyspnea, it did not alter mortality or rehospitalization, but significantly increased rates of hypotension in a large randomized controlled trial.¹² One meta-analysis encompassing three randomized controlled trials found that patients receiving nesiritide treatment had a trend toward increased 30-day mortality,¹³ but this was not confirmed by a later meta-analysis encompassing seven randomized controlled trials.¹⁴

Urodilatin, a 32-amino acid peptide that shares a similar structure to ANP, is differentially processed from pro-ANP.^15–17 Secreted by distal renal tubule cells, urodilatin decreases sodium and water reabsorption at the level of the collecting duct.^15,18 Ularitide is a synthesized analogue of human urodilatin. In animal models and clinical trials, ularitide relieved CHF symptoms and preserved renal function.¹⁹ In a phase III clinical study (TRUE-AHF), the ularitide group had greater reductions in systolic blood pressure and in levels of N-terminal pro-BNP than the placebo group.²⁰ However, short-term treatment did not affect a clinical composite end-point or reduce long-term cardiovascular mortality.^19,20

Neprilysin

Neprilysin (NEP) is a neutral endopeptidase mainly expressed in the kidneys.²¹ It degrades NPs and other vasoactive peptides such as angiotensin (ANG) II, ET-1, substance P and bradykinin.²¹ Consequently, the net physiological effect of NEP depends on the balance of its actions on vasodilators and vasoconstrictors.²¹ Valsartan/sacubitril (LCZ696), a combination of a NEP inhibitor (sacubitril) and an ARB (valsartan), is a newly US Food and Drug Administration approved drug for CHF.²² In comparison with enalapril, the PARADIGM trial showed valsartan/sacubitril reduced cardiovascular mortality and rehospitalization in patients with heart failure with reduced ejection fraction (HFrEF).²² In patients with heart failure with preserved ejection fraction (HFpEF), valsartan/sacubitril also reduced the N-terminal pro-BNP levels and improved the patients’ symptoms.²² Therefore, in addition to the conventional medications such as ACE inhibitors, ARBs, MRAs, and beta receptor blockers, valsartan/sacubitril is another promising medication for CHF.²²

Incretins

In a blood glucose-dependent manner, incretins can stimulate the pancreatic secretion of insulin.²³ Therefore, incretin-based therapies are now widely used in patients with diabetes mellitus, such as glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase (DPP)-4 inhibitors.²³ Notably, GLP-1 can act on the heart and vasculature as well, and its receptors are expressed on cardiomyocytes, coronary smooth muscle cells and endothelial cells, and human umbilical vein endothelial cells.^24–27

Incretin-based therapies exert cardioprotective effects in animal studies.²³ In dogs with pacing-induced dilated cardiomyopathy (DCM), the administration of recombinant GLP-1, GLP-1 (7-36) or GLP-1 (9-36) reduced the plasma levels of norepinephrine, decreased the LV end-diastolic pressure, heart rate (HR), and systemic vascular resistance, and improved LV function represented by stroke volume (SV), cardiac output (CO), and the LV dP/dt values.^28,29 In rats with spontaneous hypertension, GLP-1 administered for 3 months reduced cardiomyocyte apoptosis, preserved LV contractility, and further improved the survival rates.³⁰ In pigs with pacing-induced DCM, administration of a DPP-4 inhibitor sitagliptin for 3 weeks also increased SV, reduced HR, and preserved renal function.³¹

In patients with CHF after myocardial infarction (MI) or percutaneous coronary intervention, infusion of GLP-1 improves both the LV ejection fraction (LVEF) and wall motion.^28,32 In a single-center nonrandomized study, infusion of GLP-1 agonist for 5 weeks improved the LVEF, oxygen consumption, 6-min walk test (6MWT) scores, and quality of life in 12 patients with CHF (New York Heart Association [NYHA] class III/IV).³³ However, in a double-blind placebo-controlled trial, infusion of GLP-1 agonist for 48 hours had no significant effect on LV function in 15 patients with CHF (NYHA class II–III and LVEF < 40%).³⁴ A long duration of GLP-1 agonist infusion might be required to improve heart function.

Compared with these studies, large-scale clinical trials failed to show the cardioprotective roles for GLP-1 agonists and DPP-4 inhibitors beyond glucose regulation. For example, the SAVOR-TIMI 53 study is a randomized trial in patients with a history of, or those at risk of, cardiovascular events.³⁵ Within 2.1 years of follow-up, saxagliptin did not alter the incidence of cardiovascular events, whereas it increased the rates of CHF hospitalization by 27%.³⁵ The EXAMINE study, another randomized trial among patients with type 2 diabetes and a recent history of acute coronary syndrome, found that alogliptin had no significant effect on cardiovascular events during 18-months of follow-up.³⁶ The TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) trial revealed that sitagliptin had neutral effects on cardiovascular risk and CHF hospitalization among older patients with type 2 diabetes and cardiovascular disease.³⁷ Until other ongoing clinical trials such as the FIGHT (The Functional Impact of GLP-1 for Heart Failure Treatment) and CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes) studies publish their results, the clinical benefit of incretin-based therapies in CHF will remain unclear.

Growth hormone and ghrelin

Growth hormone

Growth hormone (GH) plays a crucial role for the maintenance of structure and function of normal adult hearts.^38,39 Since the myocardium and vessels secrete insulin-like growth factor-1 (IGF-1)^40–42 and express functional receptors for both GH^43–45 and IGF-1,^46,47 it is speculated that GH could directly act on the cardiovascular system as well as indirectly via the autocrine/paracrine effects of IGF-I. GH/IGF-1 can stimulate cardiac growth and contractility, and regulate vascular tone and peripheral resistance.⁴⁸

In a rat model with ischemic CHF, GH and IGF-I increased SV and CO.^49,50 In patients with CHF due to ischemia or idiopathic DCM, both short-term infusion and chronic therapy of GH improved LVEF, CO, and exercise performance.^51–53 Additionally, GH treatment in patients with CHF promoted endothelial function and nonendothelium-dependent vasodilation,⁵⁴ and decreased the levels of circulating cytokines and apoptotic agents.⁵⁵ However, in other studies in patients with CHF, although GH treatment significantly increased IGF-1 levels, it did not improve cardiac performance.^56–58 Meanwhile, in a further subgroup analysis with those that had higher serum IGF-I levels in response to GH treatment, the LVEF was also significantly increased by GH treatment.⁵⁹

Acquired GH resistance may explain these controversial results.⁵⁶ An acquired GH-resistant state has been described in CHF, with a typical pattern of high GH levels and low IGF-1 levels.⁶⁰ GH levels were increased three-fold in CHF patients with significant weight loss compared with healthy subjects and noncachectic patients; in contrast, IGF-1 levels were reduced, particularly in patients with cachexia.⁶¹ It has been shown that GH infusion produced less cardiovascular beneficial effects in patients with a lower baseline serum IGF-1.⁶² In a meta-analysis including 12 clinical trials, beneficial effects of GH treatment on LVEF and exercise parameters correlated with the extent of increased levels of serum IGF-1.⁶³ Recently, in a randomized, single-blind study, only CHF patients with GH deficiency were selected and treated with GH for 6 months.⁶⁴ GH treatment significantly increased peak oxygen uptake, exercise duration, and flow-mediated vasodilation, and improved quality of life.⁶⁴ Moreover, GH treatment led to a significant increase in LVEF and a reduction in circulating N-terminal pro-BNP levels.⁶⁴ Hence, the benefit of GH treatment in selected CHF patients, especially those with GH deficiency, might be the future direction; however, these findings need further validation in more robust clinical trials.

Ghrelin

Ghrelin, a growth hormone-releasing peptide, is an endogenous ligand of growth hormone secretagogue receptors (GHSRs).⁶⁵ The high expression of GHSR1a in the heart and large vessels provides evidence of its cardiac activity, indicating ghrelin is a promising new therapeutic agent for cardiovascular diseases.⁶⁶

In rats with chronic heart failure, ghrelin treatment attenuates the development of LV remodeling and improves LV dysfunction as indicated by the increases in CO and LV fractional shortening.⁶⁷ Activation of cardiac sympathetic nervous activity (SNA) and maladaptive remodeling is also manifested in ghrelin-deficient mice with CHF at 2 weeks after MI, accounting for the high mortality, particularly in cases that have been caused directly by HF.^68,69 Chronic treatment with metoprolol or ghrelin, which were associated with cardiac SNA inhibition and a decrease in plasma catecholamine levels, improved heart dysfunction and mortality.⁶⁸ In patients with CHF, ghrelin administration significantly decreases systemic vascular resistance and increases the CO and SV.^70,71 Furthermore, intravenous administration of ghrelin (2 µg/kg, twice a day for 3 weeks) significantly improved LVEF from 27% to 31% and increased peak workload and oxygen consumption during exercise, while dramatically decreasing plasma norepinephrine.⁷² Taken together, these findings indicate that both exogenous and endogenous ghrelin are crucial in balancing the autonomic nervous system, protecting cardiac function, and improving prognosis in CHF.⁷³ However, these effects have not been confirmed by large-scale controlled clinical trials.

Vasopressin-receptor antagonists

Arginine vasopressin (AVP) is a neurohypophysial hormone secreted from the posterior pituitary in response to decreased blood pressure and increased plasma osmolality. AVP regulates vascular tone via the nonosmotic AVP V1a receptor on vascular smooth muscle cells, and modulates volume homeostasis via the osmotic AVP V2 receptor on principal cells of the renal collecting duct.^74,75 Further, AVP contributes to cardiac fibrosis and hypertrophy at the later stages of CHF.⁷⁴

Arginine vasopressin V2 receptor selective antagonists, like tolvaptan and lixivaptan, have been studied in animal and human CHF.^76–79 In patients with CHF and preserved renal function, single doses of tolvaptan (30 mg) or furosemide (80 mg) led to a similar urine output.⁷⁸ In rats with CHF, tolvaptan dose-dependently increased the concentration of plasma sodium, whereas furosemide almost decreased it.⁸⁰ Notably, furosemide increased plasma renin activity and aldosterone concentration, whereas tolvaptan did not, implying that tolvaptan is superior to furosemide in the treatment of CHF with volume overload.⁸⁰ In addition, without inducing renal injury, the progression of LV dysfunction was halted by chronic tolvaptan treatment in rats with CHF.⁸¹ In rats with MI, chronic tolvaptan treatment also improved LVEF and reduced MI-induced remodeling such as macrophage infiltration, interstitial fibrosis, and mineralocorticoid receptor (MR) expression in the LV.^82–84 These studies indicated that tolvaptan is cardioprotective for CHF, which may be mediated by the suppression of the RAAS and inflammation.

However, neither short- nor long-term morbidity/mortality has been improved by these agents in large-scale clinical trials. For example, the ACTIV in CHF trial (Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure) evaluated the short- and intermediate-term effects of tolvaptan in symptomatic HFrEF patients.⁸⁵ Compared with the standard therapy group, the tolvaptan therapy group had a lower body weight and higher net fluid loss.⁸⁵ Although it did not affect blood pressure, HR, or electrolytes, tolvaptan did not reduce the exacerbation rate of CHF.⁸⁵ The EVEREST trial (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) evaluated the short- and long-term effects of tolvaptan in CHF patients when added to standard therapy within 48 hours of hospitalization.⁸⁶ A 60-day tolvaptan treatment period symptomatically improved heart failure without any serious side-effects, but did not improve mortality.⁸⁶ The ECLIPSE trial (Effect of Tolvaptan on Hemodynamic Parameters in Subjects with Heart Failure) evaluated the hemodynamic effects of tolvaptan in symptomatic HFrEF patients.⁸⁷ Tolvaptan dose-dependently increased urine output and levels of serum sodium without changing blood pressure (BP), HR, pulmonary and systemic vascular resistance, or cardiac index.⁸⁷

To explain the discrepancy between basic studies and clinical trials, as most clinical trials evaluated the effects of AVP antagonists in CHF patients who had been taking diuretics, these results can be confounded. Therefore, head-to-head studies are warranted to directly compare the effects of AVP antagonists with standard diuretics in the clinical setting.

Glucocorticoids and urocortins

Glucocorticoids

Stresses play a significant role in the exacerbation and progression of CHF. Glucocorticoids are the primary hormones in the response to a vast array of stresses. The actions of glucocorticoids are mediated by their glucocorticoid receptors (GR). In certain cells such as cardiomyocytes, the MRs may also be activated by glucocorticoids.⁸⁸

Acute increases in glucocorticoids can enhance cardiomyocyte contractility and promote survival under stresses; whereas sustained high levels of glucocorticoids due to chronic stress or therapeutic intervention could be hazardous to the cardiovascular system through their systemic and local effects.⁸⁸ An association between supraphysiological levels of glucocorticoids and the incidence of CHF has been demonstrated in epidemiological studies.^89,90 Patients who have sustained high levels of glucocorticoids such as those with Cushing’s syndrome will develop hypertension and metabolic syndrome, two well recognized risk factors for CHF.⁸⁸ Acute glucocorticoid administration in healthy volunteers can reduce heart rate,⁹¹ and chronic use can induce cardiac hypertrophy.^92–95 The local effects of glucocorticoids are mediated by over-activation of cardiomyocyte MR and cardiomyocyte GR, both of which lead to metabolic impairment, and translate into tissue damage, impairment of exercise capacity, and worsening symptoms.⁸⁸ Results from transgenic mice suggest that GR signaling in cardiomyocytes is critical for the normal heart function, while MR signaling participates in the development and progression of heart dysfunction.⁸⁸ Therefore, a combination of a selective GR agonist and MR antagonist might be a new therapeutic target.

Further, diuretic resistance is very common in CHF and associated with poor outcomes. Recent evidence showed that glucocorticoids may help to overcome diuretic resistance.^96,97 In a study in patients with refractory ADHF, adding prednisone (1 mg/kg per day, maximum dosage of 60 mg/day) to standard treatment doubled daily urine output, and improved CHF symptoms in 80% of patients.⁹⁸ In addition, the levels of serum creatinine were reduced in patients who received prednisone whereas unchanged in patients who received standard treatment.⁹⁸

Urocortins

Urocortin 1, 2 and 3 are a group of endogenous peptide hormones belonging to the corticotropin-releasing hormone (CRH) family.⁹⁹ The effects of urocortins are mediated by activation of central CRH receptor 1 (CRH-R1) and peripheral CRH-R2.⁹⁹ It has been shown that urocortins produce vasodilation and positive inotropic effects, and exert cardioprotective effects against ischemia-reperfusion injury.⁹⁹ They can also regulate the sympathetic nervous system and the RAAS.⁹⁹ In eight HFrEF patients, an intravenous urocortin 1 infusion was associated with high adrenocorticotropic hormone and cortisol levels and no changes in the levels of ANP or ghrelin, or any significant hemodynamic or renal effects compared with the placebo group.¹⁰⁰ In eight HFrEF patients (six with non-ischemic etiology and two with ischemic cardiomyopathy) who received low and high doses (25 µg and 100 µg) of intravenous urocortin 2, the urocortin group had increases in CO and LVEF that proportionally correlated with urocortin dose, accompanied by a reduction in mean arterial pressure, systemic peripheral resistance, and cardiac work.¹⁰¹ In a phase II study, administration of urocortin 3 in patients with HFrEF (LVEF < 35%) caused dose-dependent increases in cardiac index and reduction in systemic vascular resistance, without any effects on pulmonary capillary wedge pressure, HR or systolic BP.¹⁰² The above reports suggest that urocortins may be potential therapeutic targets of CHF.

Testosterone and estrogen

Testosterone supplementation

Low testosterone levels are common in men with CHF and are an independent risk predictor for decreased exercise capacity and poor prognosis in these patients.^103–105 Furthermore, intravenous testosterone administration in patients with CHF acutely reduces peripheral vascular resistance and increases CO.¹⁰⁶ A meta-analysis revealed that in patients with HFrEF, testosterone supplementation for 12–52 weeks was associated with an increase of exercise capacity represented by 6MWT;¹⁰⁷ although the sample size was modest and the routes of testosterone administration were different.^108–111 This degree of improvement is greater than that seen with other therapies that are currently used for morbidity and mortality reduction in patients with CHF such as ACE inhibitors, beta receptor blockers, and cardiac resynchronization therapy.^112–114 Furthermore, there was an improvement in NYHA functional class; 35% of patients in the testosterone group (versus 10% in the placebo group) had an improvement of at least 1 class.¹⁰⁷ However, this improvement occurred in the absence of cardiac structure or functional change on echocardiography; hence the improvement in exercise capacity was likely achieved via peripheral mechanisms.¹¹⁵ Nevertheless, testosterone therapy can cause water and salt retention and pose a potential safety concern. The TOM (Testosterone in Older Men with Mobility Limitations) trial was discontinued early due to significantly higher cardiovascular events in the testosterone group.¹¹⁶

Hormone replacement treatment

Several large-scale clinical trials have been conducted in examining the effects of postmenopausal hormone replacement treatment (HRT) on cardiovascular health. For example, in a primary prevention trial with 16 608 women and a mean of 5.2 years follow-up, HRT did not reduce the incidence of stroke, coronary heart disease (CHD), and pulmonary embolism.¹¹⁷ In a secondary prevention clinical trial in women with CHD, HRT did not decrease the cardiovascular events.¹¹⁸ However, recent studies proposed a timing-related benefit of HRT on CHD. When HRT was initiated in younger women (<60 years) and at an earlier stage of menopause (<10 years after onset), it reduced the total mortality and cardiovascular events; but when HRT was initiated in older women (>60 years) or at a later stage of menopause (>10 years after onset), it had no effect or a possible adverse effect on these end-points.^119–121 A large meta-analysis including 23 randomized controlled clinical trials and 39 000 women confirmed a 32% reduction of CHD incidence in women initiating HRT before 60 years of age and <10 years after menopause.¹²² This risk reduction was lost in women older than 60 years of age or in those for whom HRT was initiated > 10 years after the menopause.¹²² These results support the timing-related benefit hypothesis.¹²³ Although none of these clinical trials examined the impact of HRT on heart function or dysfunction, its involvement is nearly certain as ischemia precedes both diastolic and systolic CHF.

Thyroid Hormones

Many critical cardiovascular functions such as heart contraction, relaxation, and coronary blood flow are regulated by thyroid hormones.¹²⁴ The proper balance of thyroid hormones is necessary to maintain cardiovascular homeostasis, as both hyperthyroidism and hypothyroidism result in pathological cardiac conditions.¹²⁵

A large body of evidence suggests an increase of cardiovascular events with borderline low thyroid hormones conditions such as subclinical hypothyroidism,^126–130 which were improved after thyroid hormone treatment.^129–132 In fact, recent studies in CHF patients have also shown an increased mortality with low thyroid function.^133–135 However, this association is controversial, as one meta-analysis did not reveal a link¹³⁶ and two others did.^137,138 Moreover, no studies have examined the effects of thyroid hormone treatment on mortality in CHF patients.

Notably, the high incidence of borderline low thyroid hormone conditions implies that nearly half of CHF patients could suffer from this condition.¹²⁸ Animal experiments in CHF have indicated that low cardiac tissue triiodothyronine (T3) levels may be present even in the background of normal serum thyroid hormones.^139,140 The restoration of cardiac tissue T3 levels was associated with an improvement of LV function in rats.^139,141 However, the doses of thyroid hormone treatment needed to fully restore cardiac tissue T3 levels and improve LV function resulted in higher than normal levels of serum thyroid hormone.¹⁴¹ The actual incidence of low cardiac tissue T3 levels in CHF patients remains unknown.

Future directions

Other hormones have been studied in patients with CHF that might point to future directions. For example, serelaxin is the recombinant form of human relaxin-2, a naturally occurring peptide hormone that mediates systemic hemodynamic and renal adaptive changes during pregnancy.¹⁴² In the RELAX-AHF study, serelaxin was found to significantly improve symptoms and signs of ADHF, prevent in-hospital worsening heart failure, as well as significantly improve 180-day cardiovascular and all-cause mortality after a 48-hour infusion commenced within 16 hours of presentation.¹⁴² Sodium-glucose cotransporter-2 (SGLT2) is a protein that facilitates glucose reabsorption in the kidney.¹⁴³ SGLT2 inhibition can promote natriuresis and osmotic diuresis, leading to plasma volume contraction and reduced preload, and decreases in blood pressure, arterial stiffness, and afterload, thereby improving sub-endocardial blood flow in patients with CHF.¹⁴³ The EMPA-REG OUTCOME trial demonstrated that empagliflozin significantly reduced mortality and heart failure (HF) hospitalization risk in patients with type 2 diabetes.¹⁴⁴ The CANVAS trial subsequently reported that canagliflozin treatment reduced major adverse cardiovascular events and HF hospitalization risk in patients with type 2 diabetes using insulin.¹⁴⁵ The mechanisms responsible for the cardioprotective effects of SGLT2 inhibitors remain incompletely understood.¹⁴³ Large clinical trials with SGLT2 inhibitors are now investigating the potential use of SGLT2 inhibition in patients who have HF with and without type 2 diabetes.

In addition, HFpEF is a form of CHF where the patients presenting with HF have a normal LV ejection fraction. Although approximately 50% of patients with HF have HFpEF, there is still very little evidence regarding hormone treatments for HFpEF.¹⁴⁶ The findings of some recent studies are highlighted here. Serelaxin was well tolerated and effective in relieving dyspnea and had a similar effect on short- and long-term outcomes, including survival improvement in ADHF patients with HFpEF compared with those with HFrEF.¹⁴⁷ Treatment with a selective endothelin receptor A antagonist in HFpEF patients increased exercise tolerance but did not improve any of the secondary end-points such as LV mass or diastolic function.¹⁴⁸ In patients with pulmonary hypertension and HFpEF, endothelin receptor blockade may have no beneficial effects and could even be detrimental in comparison with a placebo.¹⁴⁹ On the other hand, in high-risk patients with HFpEF, a strategy of N-terminal pro-BNP-guided therapy (target to less than 1000 pg/ml) was not more effective than the usual care strategy in improving outcomes.¹⁵⁰

Conclusion

The prevalence of CHF has increased in the past several decades. Despite considerable advances and innovations in both medications and medical devices, the prognosis of CHF remains very poor. There is an unmet need to develop alternative or additional treatment modalities. Hormonal imbalance is a key finding and common feature in CHF, such as the over-activated RAAS, which translates into progression of the underlying disease, development of cardiovascular comorbidities, and increases in major adverse cardiovascular events. Hormonal modulation is therefore an important therapeutic strategy for CHF.

An overview of hormone therapeutics in patients with CHF is summarized in Table 1.^{9–12,21–26,28,29,35–37,43–48,63,64,66,71,72, 74–81,85–90,96–99,101,102,106,115,116,119–124,139,141} Among the discussed hormones in this review, neprilysin inhibitor is a promising drug candidate for the treatment of CHF on the top of current conventional medications. Secondly, by using an approach in the selection of CHF patients with low IGF-1 levels or low thyroid hormone levels, supplemental treatment with GH or thyroid hormone seems to be reasonable and cardioprotective. Nonetheless, there have been no clinical trials examining the long-term effects of GH or thyroid hormone treatment on cardiovascular mortality in CHF patients. Moreover, in the clinical settings of CHF with volume overload or edematous status, the AVP antagonists can relieve the symptoms without sympathetic system or the RAAS activation superior to loop diuretics. A combination of selective GR agonist and MR antagonist may represent an improved approach for glucocorticoids in the treatment of CHF, specifically in patients with diuretic resistance. Finally, the potential cardiovascular efficacy and safety of incretin-based therapies, testosterone supplementation, or HRT needs to be prudently evaluated in large-scale clinical studies.

Table 1.

Overview of hormone therapeutics in patients with congestive heart failure (CHF).

Hormones	Mechanism of action	Hemodynamic effects	Clinical outcomes	Other notes
Natriuretic peptides	Natriuresis; vasodilatation; suppressing the sympathetic activity and the RAAS⁹	Reduced pulmonary capillary wedge pressure; improved heart failure symptoms^10,11	Did not alter mortality or rehospitalization¹²
Neprilysin inhibitor	Neprilysin degrades natriuretic peptides and other vasoactive peptides²¹	Reduced N-terminal pro-BNP levels; improved symptoms²²	Reduced cardiovascular mortality and rehospitalization²²
Incretin-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors)	Incretin acts on receptors of the heart and vasculature^23–26	Decreased systemic vascular resistance; improved LV function^28,29	Neutral or increased the rates of CHF hospitalization^35–37
Growth hormone	Acts on receptors of the heart and vasculature^43–47	Promoted cardiac growth and contractility; regulate vascular tone and peripheral resistance⁴⁸	Unknown	Better effects of GH treatment on LV function in selected CHF patients with GH deficiency^63,64
Ghrelin	Receptors in the heart and large vessel; SNA inhibition⁶⁶	Increased the cardiac output^71,72	Unknown
Vasopressin receptor antagonists	Vasopressin modulates volume homeostasis; regulates vascular tone^74,75	Preserved renal function; increased urine output^76–81	Not improve in short- nor long-term morbidity/mortality^85–87
Glucocorticoids	Via glucocorticoid receptors⁸⁸	Promoted cardiomyocytes contractility; induced cardiac hypertrophy⁸⁸	Cardiovascular hazardous^88–90	Overcome diuretic resistance^96–98
Urocortins	Activation of central CRH receptors; regulates the SNA and the RAAS⁹⁹	Vasodilation and positive inotropic effects^99,101,102	Unknown
Testosterone supplementation	No improvement in cardiac function or structure; via peripheral indirect mechanisms¹¹⁵	Reduced peripheral vascular resistance; increased cardiac output¹⁰⁶	Higher cardiovascular events¹¹⁶
Estrogen replacement	Via receptors in cardiovascular systems	Unclear	Reduced the total mortality and cardiovascular events when initiated in younger women (<60 years) and earlier stage of menopause (<10 years); possible adverse effect when initiated in older women (>60 years) or later stage of menopause (>10 years)^119–123
Thyroid hormones	Via thyroid hormone receptors¹²⁴	Improvement of LV function^139,141	Unknown

RAAS, renin–angiotensin-–aldosterone system; BNP, brain natriuretic peptide; GLP-1, glucagon-like peptide-1; DPP-4, dipeptidyl peptidase-4; LV, left ventricle; GH, growth hormone; SNA, sympathetic nervous activity; CRH, corticotropin releasing hormone.

Footnotes

Declaration of conflicting interests

The authors declare that there are no conflicts of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

Kane

Karon

Mahoney

et al . Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 2011; 306: 856–863.

Fang

Mensah

Croft

et al . Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008; 52: 428–434.

Rosamond

Flegal

Furie

et al . Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25–e146.

Croft

Giles

Pollard

et al . Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999; 159: 505–510.

Lymperopoulos

Rengo

Koch

WJ.

Adrenergic nervous system in heart failure: pathophysiology and therapy.

Circ Res 2013; 113: 739–753.

De Ferrari

Schwartz

PJ.

Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions.

Heart Fail Rev 2011; 16: 195–203.

Lehmann

Stanmore

Backs

The role of endothelin-1 in the sympathetic nervous system in the heart.

Life Sci 2014; 118: 165–172.

Sayer

Bhat

The renin-angiotensin-aldosterone system and heart failure.

Cardiol Clin 2014; 32: 21–32.

Volpe

Natriuretic peptides and cardio-renal disease.

Int J Cardiol 2014; 176: 630–639.

10.

Colucci

Elkayam

Horton

et al . Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343: 246–253.

11.

Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 1531–1540.

12.

O'Connor

Starling

Hernandez

et al . Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32–43.

13.

Sackner-Bernstein

Kowalski

Fox

et al . Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005; 293: 1900–1905.

14.

Arora

Venkatesh

Molnar

Short and long-term mortality with nesiritide.

Am Heart J 2006; 152: 1084–1090.

15.

Forssmann

Richter

Meyer

The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system.

Histochem Cell Biol 1998; 110: 335–357.

16.

Saba

Ramirez

Vesely

DL.

Immunocytochemical localization of ProAnf 1–30, ProAnf 31–67, atrial natriuretic factor and urodilatin in the human kidney.

Am J Nephrol 1993; 13: 85–93.

17.

Schulz-Knappe

Forssmann

Herbst

et al . Isolation and structural analysis of “urodilatin”, a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988; 66: 752–759.

18.

Goetz

KL.

Renal natriuretic peptide (urodilatin?) and atriopeptin: evolving concepts.

Am J Physiol 1991; 261: F921–F932.

19.

Anker

Ponikowski

Mitrovic

et al . Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J 2015; 36: 715–723.

20.

Packer

O'Connor

McMurray

JJV

et al . Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med 2017; 376: 1956–1964.

21.

Solomon

Zile

Pieske

et al . The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012; 380: 1387–1395.

22.

Andersen

Simonsen

Wehland

et al . LCZ696 (valsartan/sacubitril) – a possible new treatment for hypertension and heart failure. Basic Clin Pharmacol Toxicol 2016; 118: 14–22.

23.

Takahashi

Ihara

Yamazaki

et al . Impact of either GLP-1 agonists or DPP-4 inhibitors on pathophysiology of heart failure. Int Heart J 2015; 56: 372–376.

24.

Arakawa

Mita

Azuma

et al . Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59: 1030–1037.

25.

Nystrom

Gutniak

Zhang

et al . Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209–E1215.

26.

Ishibashi

Matsui

Takeuchi

et al . Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 2010; 391: 1405–1408.

27.

Ban

Noyan-Ashraf

Hoefer

et al . Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340–2350.

28.

Nikolaidis

Elahi

Hentosz

et al . Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110: 955–961.

29.

Nikolaidis

Elahi

Shen

et al . Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005; 289: H2401–H2408.

30.

Poornima

Brown

Bhashyam

et al . Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 2008; 1: 153–160.

31.

Gomez

Touihri

Matheeussen

et al . Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail 2012; 14: 14–21.

32.

Lonborg

Vejlstrup

Kelbaek

et al . Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33: 1491–1499.

33.

Sokos

Nikolaidis

Mankad

et al . Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12: 694–699.

34.

Halbirk

Norrelund

Moller

et al . Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 2010; 298: H1096–H1102.

35.

Scirica

Bhatt

Braunwald

et al . Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317–1326.

36.

White

Cannon

Heller

et al . Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–1335.

37.

Bethel

Engel

Green

et al . Assessing the safety of sitagliptin in older participants in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes Care 2017; 40: 494–501.

38.

Sacca

Cittadini

Fazio

Growth hormone and the heart.

Endocr Rev 1994; 15: 555–573.

39.

Ren

Samson

Sowers

JR.

Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease.

J Mol Cell Cardiol 1999; 31: 2049–2061.

40.

Isgaard

Nilsson

Vikman

et al . Growth hormone regulates the level of insulin-like growth factor-I mRNA in rat skeletal muscle. J. Endocrinol 1989; 120: 107–112.

41.

D'Ercole

Stiles

Underwood

LE.

Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci U S A 1984; 81: 935–939.

42.

Delafontaine

Bernstein

Alexander

RW.

Insulin-like growth factor I gene expression in vascular cells.

Hypertension 1991; 17: 693–699.

43.

Mathews

Enberg

Norstedt

Regulation of rat growth hormone receptor gene expression.

J Biol Chem 1989; 264: 9905–9910.

44.

Isgaard

Wahlander

Adams

et al . Increased expression of growth hormone receptor mRNA and insulin-like growth factor-I mRNA in volume-overloaded hearts. Hypertension 1994; 23: 884–888.

45.

Wickman

Friberg

Adams

et al . Induction of growth hormone receptor and insulin-like growth factor-I mRNA in aorta and caval vein during hemodynamic challenge. Hypertension 1997; 29: 123–130.

46.

Guler

Zapf

Scheiwiller

et al . Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rat. Proc Natl Acad Sci U S A 1988; 85: 4889–4893.

47.

Wickman

Isgaard

Adams

et al . Inhibition of nitric oxide in rats. Regulation of cardiovascular structure and expression of insulin-like growth factor I and its receptor messenger RNA. J Hypertens 1997; 15: 751–759.

48.

Sverrisdottir

Elam

Herlitz

et al . Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. J Clin Endocrinol Metab 1998; 83: 1881–1885.

49.

Yang

Bunting

Gillett

et al . Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995; 92: 262–267.

50.

Isgaard

Kujacic

Jennische

et al . Growth hormone improves cardiac function in rats with experimental myocardial infarction. Eur J Clin Invest 1997; 27: 517–525.

51.

Fazio

Sabatini

Capaldo

et al . A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 809–814.

52.

Genth-Zotz

Zotz

Geil

et al . Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation 1999; 99: 18–21.

53.

Volterrani

Desenzani

Lorusso

et al . Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet 1997; 349: 1067–1068.

54.

Napoli

Guardasole

Matarazzo

et al . Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol 2002; 39: 90–95.

55.

Adamopoulos

Parissis

Georgiadis

et al . Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am Heart J 2002; 144: 359–364.

56.

Osterziel

Strohm

Schuler

et al . Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998; 351: 1233–1237.

57.

Isgaard

Bergh

Caidahl

et al . A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 1998; 19: 1704–1711.

58.

Acevedo

Corbalan

Chamorro

et al . Administration of growth hormone to patients with advanced cardiac heart failure: effects upon left ventricular function, exercise capacity, and neurohormonal status. Int J Cardiol 2003; 87: 185–191.

59.

Perrot

Ranke

Dietz

et al . Growth hormone treatment in dilated cardiomyopathy. J Card Surg 2001; 16: 127–131.

60.

Doehner

Pflaum

Rauchhaus

et al . Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur J Endocrinol 2001; 145: 727–735.

61.

Anker

Volterrani

Pflaum

et al . Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 2001; 38: 443–452.

62.

Giustina

Volterrani

Manelli

et al . Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. Am Heart J 1999; 137: 1035–1043.

63.

Le Corvoisier

Hittinger

Chanson

et al . Cardiac effects of growth hormone treatment in chronic heart failure: A meta-analysis. J Clin Endocrinol Metab 2007; 92: 180–185.

64.

Cittadini

Saldamarco

Marra

et al . Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J Clin Endocrinol Metab 2009; 94: 3329–3336.

65.

Kojima

Hosoda

Date

et al . Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656–660.

66.

Marleau

Mulumba

Lamontagne

et al . Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies. Cardiovasc Res 2006; 69: 26–35.

67.

Nagaya

Uematsu

Kojima

et al . Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001; 104: 1430–1435.

68.

Mao

Tokudome

Otani

et al . Excessive sympathoactivation and deteriorated heart function after myocardial infarction in male ghrelin knockout mice. Endocrinology 2013; 154: 1854–1863.

69.

Mao

Tokudome

Kishimoto

et al . Hexarelin treatment in male ghrelin knockout mice after myocardial infarction. Endocrinology 2013; 154: 3847–3854.

70.

Nagaya

Kojima

Uematsu

et al . Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1483–R1487.

71.

Enomoto

Nagaya

Uematsu

et al . Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans. Clin Sci (Lond) 2003; 105: 431–435.

72.

Nagaya

Moriya

Yasumura

et al . Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110: 3674–3679.

73.

Mao

Tokudome

Kishimoto

Ghrelin as a treatment for cardiovascular diseases.

Hypertension 2014; 64: 450–454.

74.

Lee

Watkins

Patterson

et al . Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003; 146: 9–18.

75.

Costello-Boerrigter

Smith

Boerrigter

et al . Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006; 290: F273–F278.

76.

Rehsia

Dhalla

NS.

Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.

Heart Fail Rev 2010; 15: 85–101.

77.

Valania

Singh

Slawsky

MT.

Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists?

Curr Heart Fail Rep 2011; 8: 198–205.

78.

Udelson

Bilsker

Hauptman

et al . A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail 2011; 17: 973–981.

79.

Abraham

Shamshirsaz

McFann

et al . Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006; 47: 1615–1621.

80.

Veeraveedu

Watanabe

et al . Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem Pharmacol 2008; 75: 1322–1330.

81.

Morooka

Iwanaga

Tamaki

et al . Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circ Heart Fail 2012; 5: 484–492.

82.

Kuwahara

Nishikimi

Nakao

Transcriptional regulation of the fetal cardiac gene program.

J Pharmacol Sci 2012; 119: 198–203.

83.

Yamazaki

Izumi

Nakamura

et al . Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats. Circ Heart Fail 2012; 5: 794–802.

84.

Yamazaki

Nakamura

Shiota

et al . Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats. J Pharmacol Sci 2013; 123: 58–66.

85.

Gheorghiade

Gattis

O'Connor

et al . Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963–1971.

86.

Gheorghiade

Konstam

Burnett

et al . Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332–1343.

87.

Udelson

Orlandi

Ouyang

et al . Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 1540–1545.

88.

Oakley

Cidlowski

JA.

Glucocorticoid signaling in the heart: a cardiomyocyte perspective.

J Steroid Biochem Mol Biol 2015; 153: 27–34.

89.

Souverein

Berard

Van Staa

et al . Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90: 859–865.

90.

Wei

MacDonald

Walker

BR.

Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease.

Ann Intern Med 2004; 141: 764–770.

91.

Brotman

Girod

Garcia

et al . Effects of short-term glucocorticoids on cardiovascular biomarkers. J Clin Endocrinol Metab 2005; 90: 3202–3208.

92.

Whitehurst

Zhang

Bhattacharjee

et al . Dexamethasone-induced hypertrophy in rat neonatal cardiac myocytes involves an elevated L-type Ca(2+)current. J Mol Cell Cardiol 1999; 31: 1551–1558.

93.

Ren

Oakley

Cruz-Topete

et al . Dual role for glucocorticoids in cardiomyocyte hypertrophy and apoptosis. Endocrinology 2012; 153: 5346–5360.

94.

La Mear

MacGilvray

Myers

TF.

Dexamethasone-induced myocardial hypertrophy in neonatal rats.

Biol Neonate 1997; 72: 175–180.

95.

Lister

Autelitano

Jenkins

et al . Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: A possible role for SGK1. Cardiovasc Res 2006; 70: 555–565.

96.

Liu

Zhou

et al . Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance. Can J Cardiol 2007; 23: 865–868.

97.

Liu

Chen

Zhou

et al . Potent potentiating diuretic effects of prednisone in congestive heart failure. J Cardiovasc Pharmacol 2006; 48: 173–176.

98.

Liu

Effects of glucocorticoids in potentiating diuresis in heart failure patients with diuretic resistance.

J Card Fail 2014; 20: 625–629.

99.

Walczewska

Dzieza-Grudnik

Siga

et al . The role of urocortins in the cardiovascular system. J Physiol Pharmacol 2014; 65: 753–766.

100.

Davis

Pemberton

Yandle

et al . Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin Sci (Lond) 2005; 109: 381–388.

101.

Davis

Pemberton

Yandle

et al . Urocortin 2 infusion in human heart failure. Eur Heart J 2007; 28: 2589–2597.

102.

Gheorghiade

Greene

Ponikowski

et al . Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. Eur J Heart Fail 2013; 15: 679–689.

103.

Jankowska

Biel

Majda

et al . Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006; 114: 1829–1837.

104.

Jankowska

Filippatos

Ponikowska

et al . Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J Card Fail 2009; 15: 442–450.

105.

Malkin

Pugh

Morris

et al . Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010; 96: 1821–1825.

106.

Pugh

Jones

Channer

KS.

Acute haemodynamic effects of testosterone in men with chronic heart failure.

Eur Heart J 2003; 24: 909–915.

107.

Toma

McAlister

Coglianese

et al . Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 2012; 5: 315–321.

108.

Caminiti

Volterrani

Iellamo

et al . Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54: 919–927.

109.

Malkin

Pugh

West

et al . Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006; 27: 57–64.

110.

Pugh

Jones

West

et al . Testosterone treatment for men with chronic heart failure. Heart 2004; 90: 446–447.

111.

Iellamo

Volterrani

Caminiti

et al . Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2010; 56: 1310–1316.

112.

Olsson

Swedberg

Clark

et al . Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J 2005; 26: 778–793.

113.

McAlister

Ezekowitz

Hooton

et al . Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007; 297: 2502–2514.

114.

Young

Abraham

Smith

et al . Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003; 289: 2685–2694.

115.

Armstrong

Ezekowitz

JA.

Testosterone therapy in women with heart failure: “Why can't a woman be more like a man?

J Am Coll Cardiol 2010; 56: 1317–1319.

116.

Basaria

Coviello

Travison

et al . Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109–122.

117.

Rossouw

Anderson

Prentice

et al . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333.

118.

Grady

Herrington

Bittner

et al . Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49–57.

119.

Hodis

Collins

Mack

et al . The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric 2012; 15: 217–228.

120.

Hodis

Mack

WJ.

The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 1: comparison of therapeutic efficacy.

J Am Geriatr Soc 2013; 61: 1005–1010.

121.

Hodis

Mack

WJ.

The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 2: comparative risks.

J Am Geriatr Soc 2013; 61: 1011–1018.

122.

Salpeter

Walsh

Greyber

et al . Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006; 21: 363–366.

123.

Clarkson

Melendez

Appt

SE.

Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future.

Menopause 2013; 20: 342–353.

124.

Klein

Ojamaa

Thyroid hormone and the cardiovascular system.

N Engl J Med 2001; 344: 501–509.

125.

Mullur

Liu

Brent

GA.

Thyroid hormone regulation of metabolism.

Physiol Rev 2014; 94: 355–382.

126.

Chen

Shauer

Zwas

et al . The effect of thyroid function on clinical outcome in patients with heart failure. Eur J Heart Fail 2014; 16: 217–226.

127.

Hak

Pols

Visser

et al . Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med 2000; 132: 270–278.

128.

Iervasi

Pingitore

Landi

et al . Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 2003; 107: 708–713.

129.

Imaizumi

Akahoshi

Ichimaru

et al . Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 2004; 89: 3365–3370.

130.

Kahaly

GJ.

Cardiovascular and atherogenic aspects of subclinical hypothyroidism.

Thyroid 2000; 10: 665–679.

131.

Pingitore

Galli

Barison

et al . Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008; 93: 1351–1358.

132.

Razvi

Ingoe

Keeka

et al . The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab 2007; 92: 1715–1723.

133.

Chuang

Jong

et al . Impact of triiodothyronine and N-terminal pro-B-type natriuretic peptide on the long-term survival of critically ill patients with acute heart failure. Am J Cardiol 2014; 113: 845–850.

134.

Mitchell

Hellkamp

Mark

et al . Thyroid function in heart failure and impact on mortality. JACC Heart Fail 2013; 1: 48–55.

135.

Tseng

Lin

et al . Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. J Am Coll Cardiol 2012; 60: 730–737.

136.

Rodondi

den Elzen

Bauer

et al . Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010; 304: 1365–1374.

137.

Haentjens

Van Meerhaeghe

Poppe

et al . Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 2008; 159: 329–341.

138.

Ochs

Auer

Bauer

et al . Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008; 148: 832–845.

139.

Liu

Redetzke

Said

et al . Serum thyroid hormone levels may not accurately reflect thyroid tissue levels and cardiac function in mild hypothyroidism. Am J Physiol Heart Circ Physiol 2008; 294: H2137–H2143.

140.

Weltman

Ojamaa

Schlenker

et al . Low-dose T₃ replacement restores depressed cardiac T₃ levels, preserves coronary microvasculature and attenuates cardiac dysfunction in experimental diabetes mellitus. Mol Med 2014; 20: 302–312.

141.

Weltman

Ojamaa

Savinova

et al . Restoration of cardiac tissue thyroid hormone status in experimental hypothyroidism: a dose-response study in female rats. Endocrinology 2013; 154: 2542–2552.

142.

Diez

Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.

Am J Cardiovasc Drugs 2014; 14: 275–285.

143.

Lytvyn

Bjornstad

Udell

et al . Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 2017; 136: 1643–1658.

144.

Wanner

Inzucchi

Lachin

et al . Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323–334.

145.

Neal

Perkovic

de Zeeuw

et al . Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015; 38: 403–411.

146.

Dunlay

Roger

Redfield

MM.

Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2017; 14: 591–602.

147.

Filippatos

Teerlink

Farmakis

et al . Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J 2014; 35: 1041–1050.

148.

Zile

Bourge

Redfield

et al . Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. JACC Heart Fail 2014; 2: 123–130.

149.

Koller

Steringer-Mascherbauer

Ebner

et al . Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-Trial). Heart Lung Circ 2017; 26: 433–441.

150.

Felker

Anstrom

Adams

et al . Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2017; 318: 713–720.

Hormone treatments in congestive heart failure

Abstract

Keywords

Introduction

Natriuretic peptides and neprilysin

Natriuretic peptides

Neprilysin

Incretins

Growth hormone and ghrelin

Growth hormone

Ghrelin

Vasopressin-receptor antagonists

Glucocorticoids and urocortins

Glucocorticoids

Urocortins

Testosterone and estrogen

Testosterone supplementation

Hormone replacement treatment

Thyroid Hormones

Future directions

Conclusion

Footnotes

Declaration of conflicting interests

Funding

References